Background: Activated factor VII catalyzes the activation of clotting factors IX and X within the
clotting cascade, and has been used clinically to decrease bleeding in patients with …

Background Recombinant factor VIIa (rFVIIa) is used for treatment of bleeding episodes in
hemophilia patients who develop inhibitors to factors VIII and IX. We tested the hypothesis …

Background Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a
number of settings including hemophilia, liver transplantation, intractable bleeding, and …

Background Recombinant factor VIIa (rFVIIa) is used for treatment of bleeding episodes in
hemophilia patients who develop inhibitors to factors VIII and IX. We tested the hypothesis …

Abstract Background Recombinant factor VIIa (rFVIIa) has been successfully used in various
clinical conditions to treat severe coagulopathy, but its efficacy may be affected by the …

Background: Uncontrolled bleeding is a leading cause of death in trauma. Two randomized,
placebo-controlled, double-blind trials (one in blunt trauma and one in penetrating trauma) …

BACKGROUND: Recombinant Factor VIIa (rFVIIa) has been used to decrease bleeding in a
number of settings, including hemophilia, liver transplantation, intractable bleeding, and …

INTRODUCTION: Coagulopathy in injured patients is common and is generally treated with
fresh frozen plasma (FFP). Response can be variable, thus complete correction may take …

In this article we describe the current use of recombinant activated factor VII (rFVIIa;
NovoSeven®) in trauma patients. Emphasis is placed on current uses as defined by key …

Background: Hemorrhage is the leading cause of death in battlefield casualties and the
second leading cause of death after civilian trauma. Evacuation time for military casualties to …